Ascendis製藥 ASND 深 滬

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics appoints Jesper Høiland as Head of Strategy, leveraging his 30+ years of global pharma experience, particularly in obesity and metabolic diseases. Høiland, previously a strategic adviser, will lead corporate and pipeline strategy, prioritize programs, and support partnerships to maximize clinical and market potential. His expertise includes successful development and commercialization of therapies like Novo Nordisk’s insulin ana...

03-25 20:53

Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech

RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), am...

03-20 02:37

BioMarin stops mid-stage trials of bone disorder treatment

BioMarin stops mid-stage trials of bone disorder treatment March 16 (Reuters) - BioMarin Pharmaceutical BMRN.O will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker said on Monday, sending its share

03-16 21:34

Ascendis Pharma Announces Data From Pivotal ApproaCH Trial Showing Children With Achondroplasia Treated With Once-Weekly TransCon CNP Maintained Consistent Improvements In Growth Through Week 104, With Further Improvement In Body Proportionality During Second Year Of Treatment

Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained consistent

03-16 20:06

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

03-16 12:00

美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价

今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元

03-04 10:22

Ascendis Pharma Receives FDA Approval For YUVIWEL For Children With Achondroplasia Aged 2 Years and Older; Commercial Availability Expected During Early Part Of Q2 2026; Rare Pediatric Disease Priority Review Voucher Granted In Connection With Approval

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease

02-28 07:03

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

Ascendis Pharma's YUVIWEL, the first weekly treatment for achondroplasia, received FDA approval under the Accelerated Approval Program. It provides continuous systemic exposure to CNP over weekly dosing. YUVIWEL is indicated for children 2 years and older with open epiphyses. Commercial availability is expected in early Q2 2026. A Rare Pediatric Disease Priority Review Voucher was granted. Ascendis will host an investor call on March 2 to discuss...

02-27 22:57

Ascendis Pharma A/S Announces Annual General Meeting

Ascendis Pharma A/S Announces Annual General Meeting Ascendis Pharma A/S will hold its annual general meeting on March 23, 2026 in Copenhagen, Denmark. Shareholders will vote on the election of the chair of the meeting; a report on the company’s activities during the past year; approval of the audit

02-24 05:08

美股大行评级 | AppLovin评级分歧大！高盛等4家下调，韦德布什上调；HubSpot、休曼纳公司、Shopify、Unity、Paycom Software等遭多家大行下调目标价

今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从39美元升至47美元；HC Wainwright & Co.：维持Agios制药"买入"评级，目标价从62美元升至65美元

02-13 15:30